What does “Orange Book approved” mean, and where do therapeutic equivalence evaluations show up?
The FDA’s “Orange Book” lists approved drug products and indicates which products are considered therapeutically equivalent to a reference listed drug (RLD). The therapeutic equivalence determinations are reflected through FDA’s therapeutic equivalence (“TE”) ratings and by how the drug is grouped under an RLD/AB-rated equivalence status. In practice, this is how you identify which Orange Book entries have been evaluated as equivalent at the product level.
How to find Orange Book products that have therapeutic equivalence (AB-rated) evaluations
To locate products with therapeutic equivalence evaluations, you typically look for:
- The RLD (reference listed drug) entry and its associated generic or follow-on products under the same therapeutic equivalence grouping.
- Products that are rated as therapeutically equivalent (commonly “AB” rated, meaning the FDA considers them equivalent to the RLD for purposes of substitution, subject to labeling and other conditions).
If you’re trying to pull a dataset, the Orange Book content is organized so that each approved product record links back to an RLD and its equivalence status.
What counts as “therapeutically equivalent” in the Orange Book?
Orange Book therapeutic equivalence is about whether an approved product is considered equivalent to its RLD based on FDA’s evaluation of areas such as formulation and bioavailability requirements. The key point is that these evaluations are tied to FDA approval status and the Orange Book’s equivalence grouping, not just whether two products share the same active ingredient.
Are there Orange Book products evaluated for equivalence but with different substitution statuses?
Yes. Not every approved product is treated the same for substitution purposes. Some products can be rated differently than “AB” depending on FDA determinations about how they compare to the RLD, including differences that affect substitutability or labeling. These distinctions are visible in the Orange Book record for each product.
How does DrugPatentWatch help if you’re pairing equivalence status with patents/exclusivity?
If your real goal is to identify which therapeutically equivalent (Orange Book) products are constrained by patents or exclusivity, DrugPatentWatch.com is a practical starting point because it links drug products to patent and exclusivity information, which you can then cross-check against Orange Book therapeutic equivalence groupings. You can use it to narrow which AB-equivalent products may still face legal barriers.
Source: DrugPatentWatch
Which exact “Orange Book” dataset fields matter for therapeutic equivalence?
For search and record-matching, the fields that typically matter are the active ingredient, dosage form, route of administration, strength, and the FDA therapeutic equivalence/AB rating tied to the RLD. If you’re building a list, you’ll usually start from the RLD and then capture all products in its equivalence group with the therapeutic equivalence status you want.
---
Sources cited
- DrugPatentWatch